Martin MD - Xilio Development Pres RD
| XLO Stock | USD 0.88 0.01 1.12% |
Insider
Martin MD is Pres RD of Xilio Development
| Age | 63 |
| Address | 828 Winter Street, Waltham, MA, United States, 02451 |
| Phone | 857 524 2466 |
| Web | https://xiliotx.com |
Xilio Development Management Efficiency
The company has Return on Asset of (0.5258) % which means that on every $100 spent on assets, it lost $0.5258. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.7096) %, meaning that it generated no profit with money invested by stockholders. Xilio Development's management efficiency ratios could be used to measure how well Xilio Development manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -1.32. In addition to that, Return On Capital Employed is likely to drop to -1.85. At this time, Xilio Development's Total Assets are very stable compared to the past year. As of the 26th of November 2024, Net Tangible Assets is likely to grow to about 127.6 M, while Non Currrent Assets Other are likely to drop about 937.9 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Gwen Carscadden | RAPT Therapeutics | 63 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Lynn Scherm | Tyra Biosciences | N/A | |
| Steven Chan | Connect Biopharma Holdings | 52 | |
| Ronald Swanson | Tyra Biosciences | 60 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Guizhong Liu | Adagene | 53 | |
| Hunter MD | Aerovate Therapeutics | 58 | |
| MBA MD | Ikena Oncology | 59 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| Amy Conrad | Tyra Biosciences | N/A | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Fangyong Du | Adagene | 54 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Joseph Zakrzewski | AN2 Therapeutics | 62 | |
| George Eldridge | Aerovate Therapeutics | 61 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
Management Performance
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.53 |
Xilio Development Leadership Team
Elected by the shareholders, the Xilio Development's board of directors comprises two types of representatives: Xilio Development inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xilio. The board's role is to monitor Xilio Development's management team and ensure that shareholders' interests are well served. Xilio Development's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xilio Development's outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD BCPS, CEO President | ||
| Kevin Brennan, Senior Accounting | ||
| Martin MD, Pres RD | ||
| Scott Coleman, Chief Officer | ||
| Uli Bialucha, Chief Officer | ||
| Bill Avery, VP Devel | ||
| BCPS PharmD, CEO Director | ||
| Katarina MD, Chief Officer | ||
| Julissa Viana, Vice Communications | ||
| Stacey Davis, Chief Officer | ||
| Christopher Frankenfield, Chief Officer |
Xilio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xilio Development a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.71 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (6.54) % | ||||
| Current Valuation | (13.63 M) | ||||
| Shares Outstanding | 43.96 M | ||||
| Shares Owned By Insiders | 40.92 % | ||||
| Shares Owned By Institutions | 33.50 % | ||||
| Number Of Shares Shorted | 396.08 K | ||||
| Price To Book | 1.87 X | ||||
| Price To Sales | 8.49 X |
Pair Trading with Xilio Development
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xilio Development position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xilio Development will appreciate offsetting losses from the drop in the long position's value.Moving against Xilio Stock
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.65 | MTEM | Molecular Templates | PairCorr |
| 0.63 | TPST | Tempest Therapeutics | PairCorr |
| 0.56 | ME | 23Andme Holding | PairCorr |
| 0.55 | IPSC | Century Therapeutics | PairCorr |
The ability to find closely correlated positions to Xilio Development could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xilio Development when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xilio Development - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xilio Development to buy it.
The correlation of Xilio Development is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xilio Development moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xilio Development moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xilio Development can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xilio Development. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Xilio Stock, please use our How to Invest in Xilio Development guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xilio Development. If investors know Xilio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xilio Development listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 0.105 | Return On Assets (0.53) | Return On Equity (1.71) |
The market value of Xilio Development is measured differently than its book value, which is the value of Xilio that is recorded on the company's balance sheet. Investors also form their own opinion of Xilio Development's value that differs from its market value or its book value, called intrinsic value, which is Xilio Development's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xilio Development's market value can be influenced by many factors that don't directly affect Xilio Development's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xilio Development's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xilio Development is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xilio Development's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.